SLC35G6: A Potential Drug Target and Biomarker for Neurological Disorders

Target Name: SLC35G6

NCBI ID: G643664

SLC35G6

SLC35G6: A Potential Drug Target and Biomarker for Neurological Disorders

Sodium-dependent cysteine transmembrane protein 6 (SLC35G6) is a protein that is expressed in various tissues and cells in the body. It is a member of the SLC family of proteins, which are known for their ability to transport and regulate the concentration of solutes and ions across cell membranes. SLC35G6 is specifically known for its ability to transport cysteine, a molecule that is involved in various cellular processes, including protein synthesis and stress response.

SLC35G6 has been shown to play a role in a number of neurological disorders, including Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders. In these conditions, the misfolded proteins that are produced by SLC35G6 and other genes can accumulate and form aggregates that are thought to contribute to the development and progression of the disease.

One of the unique features of SLC35G6 is its ability to form aggregates that are resistant to many conventional therapies, including those for neurodegenerative disorders. This makes it an attractive potential drug target and biomarker for these conditions.

SLC35G6 has also been shown to be involved in the regulation of cellular stress responses, which are critical for the survival and proper functioning of cells. In response to stress, cells produce a variety of proteins that help to protect their integrity and maintain their structural stability. SLC35G6 is one of these proteins, and it has been shown to play a key role in regulating stress responses in cells.

One of the key challenges in studying SLC35G6 and its role in neurological disorders is the difficulty of studying a protein that is expressed in such a wide range of cell types and contexts. This makes it difficult to determine exactly how SLC35G6 contributes to the development and progression of these conditions. However, research into SLC35G6 and its potential drug targets is ongoing, and it holds promise as a new treatment option for a range of neurological disorders.

In conclusion, SLC35G6 is a transmembrane protein that is involved in the regulation of various cellular processes, including stress responses and protein synthesis. It has been shown to play a role in the development and progression of a number of neurological disorders, including Alzheimer's disease and Parkinson's disease. Its unique ability to form aggregates that is resistant to many conventional therapies makes it an attractive potential drug target and biomarker for these conditions. Further research is needed to fully understand the role of SLC35G6 in these disorders and to develop new treatments based on its properties.

Protein Name: Solute Carrier Family 35 Member G6

The "SLC35G6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC35G6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets